Skip to main content
Home > SciBX > Public-Private

Chronological Index of : Public-Private Interface

 Current Issue
  • Table 1: Evotec's partnerships with universities and research organizations

    Public-Private Interface: Evotec's growing Ivy Table 1. Evotec's partnerships with universities and research organizations. Evotec AG's Open Innovation Alliance with Yale University is among the few drug discovery …

    Published on 1/31/2013
  • Evotec's growing Ivy

    Evotec is double dipping into the Ivy League, this time partnering with Yale University to move early stage research from the university's labs into late preclinical and IND-ready assets for third parties to license. …

    Published on 1/31/2013
  • Table 1: 2012 CIRM grants

    Public-Private Interface: CIRM: get a little closer Table 1. 2012 CIRM grants. Research grants awarded by the California Institute for Regenerative Medicine (CIRM) to develop stem cell-based therapies. Source: CIRM…

    Published on 8/16/2012
  • Table 2: Update on 2009 CIRM grants

    Public-Private Interface: CIRM: get a little closer Table 2. Update on 2009 CIRM grants. Status of research grants awarded in 2009 by the California Institute for Regenerative Medicine (CIRM) to develop stem cell-…

    Published on 8/16/2012
  • CIRM: get a little closer

    The California Institute for Regenerative Medicine's latest batch of grants reflects its interest in funding projects that are close to entering the clinic.

    Published on 8/16/2012
  • IMI's leadoff hitter

    Europe's Innovative Medicines Initiative has recruited 7 pharmas to each contribute up to 50,000 compounds from their proprietary libraries for a public-private partnership called the European Lead Factory. The pharmas …

    Published on 3/29/2012
  • Gap-filling alliance

    Instead of taking discoveries from universities and forming companies, BioPontis starts with its knowledge of industry's portfolio needs and works backward. Its alliance so far includes Merck, Pfizer, Janssen Biotech …

    Published on 8/4/2011
  • Making the case for precompetitive clinical development

    Sage Bionetworks and the Structural Genomics Consortium are spearheading an effort to build a pharma-backed public-private partnership to clinically validate new targets in an IP-free, precompetitive environment. The …

    Published on 5/19/2011
  • Agilent synthesizes partnerships

    Agilent is using academic partnerships to get in on the ground floor of synthetic biology, an area the company deems strategically important because it encompasses all three of Agilent's core business areas: electronic …

    Published on 5/12/2011
  • Translational biology with a clinical mindset

    Attracted by INSERM's large network of labs and hospitals, MedImmune has formed a strategic collaboration with the institute to explore translational biology and new disease mechanisms and streamline the flow of drug …

    Published on 4/28/2011
  • KICk-starting European enterprise

    After cutting its teeth with investments in energy and communications, the European Institute for Innovation and Technology is moving into the biopharmaceutical space with plans for a round of seed-stage financing.

    Published on 3/10/2011
  • Singapore's new tune

    After more than two decades of investing in life science infrastructure, Singapore is shifting its focus and allotting $2.8 billion over the next 5 years to translational research with near-term commercial applications …

    Published on 10/28/2010
  • Beta testing in diabetes

    Three recent collaborations are seeking to develop type 1 diabetes therapies that induce insulin-producing cells to regenerate. The compounds could eventually bypass the need for cell therapy, but they still require …

    Published on 4/29/2010
  • Orienting cancer

    Lilly, Merck and Pfizer have joined in a precompetitive deal to study the pharmacogenomics of Asian cancer patients. They expect to triple the power of the resulting open-source database at a third of the cost to each …

    Published on 3/11/2010
  • Table 1: CIRM Grants

    CIRM's Expanding Reach Table 1. CIRM grants. Below is a list of 14 research grants awarded by the California Institute for Regenerative Medicine (CIRM) to develop stem cell-based therapies. Lead institution Lead …

    Published on 11/12/2009
  • CIRM's expanding reach

    The California Institute for Regenerative Medicine is moving beyond early translation, with its latest grants aiming to produce IND submissions. The awards also begin to reflect CIRM's collaboration with agencies …

    Published on 11/12/2009
  • Table: CIRM-funded translational research

    Public-Private Interface: CIRM's clinical mindset Table 1. CIRM-funded translational research. Institution Grant ($M) Indication Stem cell therapies Burnham Institute for Medical Research $3.5 Parkinson's …

    Published on 5/7/2009
  • CIRM's clinical mindset

    The California Institute for Regenerative Medicine has issued $68 million in grants specifically aimed at moving stem cell research closer to the clinic. The initial winners are institutes and companies focused on …

    Published on 5/7/2009
  • Follow-up: IMI Unveils First Call

    Europe's Innovative Medicines Initiative officially unveiled the first 18 projects it will fund under a 5-year, 2 billion program to relieve bottlenecks in drug discovery and development, and for the first time it …

    Published on 5/8/2008
  • Table 1. Innovative Medicines Initiative Projects

    Public Private Interface: Follow-up: IMI Unveils First Call Table 1. Innovative Medicines Initiative projects. The first call for 18 projects as part of the Innovative Medicines Initiative (IMI) was recently released…

    Published on 5/8/2008
  • Europe's Biomarker Push

    The European Commission is readying the first call for projects under its Innovative Medicines Initiative with the European Federation of Pharmaceutical Industries and Associations, which will invest some EUR 205 …

    Published on 3/27/2008
  • Table 1. Innovative Medicines Initiative Principles on IP

    Public Private Interface: Europe's Biomarker Push Table 1. Innovative Medicines Initiative principles on IP. European Federation of Pharmaceutical Industries and Associations members and the European Commission …

    Published on 3/27/2008

 
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993